OCEANSIDE, CA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)THE BIOMEDICAL RESEARCH INSTITUTE OF SOUTHERN CALIFORNIA, founded in 2011, is a small nonprofit in the Medical Research sector that reported $208K in total revenue in fiscal year 2023. Revenue surged 188% from the prior year, signaling strong growth momentum. Expenses of $189K left a modest 9% surplus.
THE MISSION OF THIS ORGANIZATION IS TO CONDUCT SCIENTIFIC RESEARCH AIMED AT CURING OR PREVENTING HUMAN DISEASE. WE WILL CONDUCT BASIC RESEARCH AIMED AT UNDERSTANDING THE FUNDAMENTAL MECHANISMS OF NORMAL BIOLOGICAL PROCESSES AND HOW THESE DIFFER IN DISEASE STATES. THIS WILL HELP US TO IDENTIFY NEW WAYS TO DIAGNOSE, PREVENT OR TREAT HUMAN DISEASE. WE WILL ALSO CONDUCT PRECLINICAL DISCOVERY RESEARCH INTO DEVELOPING AND TESTING NOVEL VACCINES AND THERAPEUTIC AGENTS FOR HUMAN DISEASE.
VIRAL IMMUNOLOGYTHE OBJECTIVE OF THIS PROGRAM IS TO CONDUCT RESEARCH INTO THE MECHANISMS BY WHICH THE IMMUNE SYSTEM PROTECTS AGAINST VIRAL INFECTIONS. THIS RESEARCH WILL HELP US TO DEVELOP BETTER...
VIRAL IMMUNOLOGYTHE OBJECTIVE OF THIS PROGRAM IS TO CONDUCT RESEARCH INTO THE MECHANISMS BY WHICH THE IMMUNE SYSTEM PROTECTS AGAINST VIRAL INFECTIONS. THIS RESEARCH WILL HELP US TO DEVELOP BETTER VACCINES AND THERAPEUTIC AGENTS FOR VIRAL INFECTIONS. THIS PROGRAM INCLUDES PRE-CLINICAL WORK ON A NOVEL UNIVERSAL INFLUENZA VACCINE, THE MECHANISM BY WHICH IT PROTECTS AGAINST MULTIPLE STRAINS OF INFLUENZA AND WHETHER THE VACCINE PROTECTS AGAINST SECONDARY BACTERIAL INFECTIONS OFTEN INCREASE MORTALITY FROM INFLUENZA. WE ARE ALSO INVESTIGATING NOVEL VACCINE ADJUVANTS AND WHY IMMUNE RESPONSES TO CERTAIN VACCINES WANE OVER TIME.
DIABETESTHE GOAL OF THIS PROGRAM IS TO IDENTIFY UNIQUE EVENTS AND MOLECULAR PATHWAYS THAT CAN TRIGGER THE AUTOREACTIVE T CELLS TO CAUSE DESTRUCTION OF THE PANCREATIC ISLETS IN TYPE 1 DIABETES. THE...
DIABETESTHE GOAL OF THIS PROGRAM IS TO IDENTIFY UNIQUE EVENTS AND MOLECULAR PATHWAYS THAT CAN TRIGGER THE AUTOREACTIVE T CELLS TO CAUSE DESTRUCTION OF THE PANCREATIC ISLETS IN TYPE 1 DIABETES. THE ROLE OF EXOSOMES AND NOVEL SELF-ANTIGENS ENCODED BY ENDOGENOUS RETROVIRUSES IS A MAJOR FOCUS OF THIS STUDY.
THE BLOOD BRAIN BARRIERTHE BLOOD-BRAIN BARRIER (BBB) PREVENTS BLOODBORNE SUBSTANCES FROM NON-SELECTIVELY CROSSING INTO THE BRAIN AND PLAYS A CRUCIAL ROLE IN PROTECTING THE BRAIN FROM HARMFUL...
THE BLOOD BRAIN BARRIERTHE BLOOD-BRAIN BARRIER (BBB) PREVENTS BLOODBORNE SUBSTANCES FROM NON-SELECTIVELY CROSSING INTO THE BRAIN AND PLAYS A CRUCIAL ROLE IN PROTECTING THE BRAIN FROM HARMFUL SUBSTANCES AND PATHOGENS. HOWEVER, THE BBB ALSO SIGNIFICANTLY IMPEDES THE DELIVERY OF THERAPEUTIC AGENTS INTO THE BRAIN WHICH PRESENTS A MAJOR CHALLENGE FOR THE TARGETING AND DELIVERY OF PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF VARIOUS CENTRAL NERVOUS SYSTEM (CNS) DISEASES, INCLUDING CANCERS, HIV INFECTION AND ALZHEIMER'S DISEASE. BRISC SCIENTISTS ARE STUDYING THE ROLE OF THE BBB IN HEALTH AND DISEASE AND ARE CONDUCTING COLLABORATIVE STUDIES ON NOVEL METHODS OF REVERSIBLY PERMEABILIZING THE BBB TO ALLOW ENTRY OF THERAPEUTIC AGENTS.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $208,249 | $72,428 | +1.9% |
| Expenses | $188,995 | $91,029 | +1.1% |
| Net Income | $19,254 | $-18,601 | -2.0% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| DR CRAIG JACKSON | CHAIRMAN OF BOARD OF DIREC | 0.50 |
Director
|
$0 | $0 | $0 |
| DR LEMAN YEL | DIRECTOR | 0.30 |
Director
|
$0 | $0 | $0 |
| DR PETER DIAS | CFO | 20.00 |
Officer
Director
|
$0 | $0 | $0 |
| MR MICHAEL GISKE | DIRECTOR | 0.50 |
Director
|
$0 | $0 | $0 |
| DR SALLY SARAWAR | PRESIDENT AND CEO | 20.00 |
Officer
|
$34,683 | $0 | $34,683 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2023 | $208,249 | $188,995 | $60,330 | $19,254 |
| 2020 | $352,753 | $352,568 | $52,606 | $185 |
| 2019 | $924,036 | $923,840 | $52,547 | $196 |
| 2018 | $818,213 | $818,116 | $83,144 | $97 |
Compare THE BIOMEDICAL RESEARCH INSTITUTE OF SOUTHERN CALIFORNIA with other nonprofits in California and across the country.